by Anthony Palmeri | Oct 19, 2026
A candid look at what investors want to see in a neuromuscular disease program.
by Anthony Palmeri | Oct 19, 2026
A tour of every approach being pursued for CMT, from small molecules to gene therapy to AI-accelerated drug discovery.
by Anthony Palmeri | Oct 19, 2026
Many seemingly unrelated genetic diseases converge on shared “nodal” pathways — which means the next CMT breakthrough could come from a lab studying something else entirely.
